# Pembrolizumab as First-line Treatment for Advanced NSCLC Complicated With COPD

> **NCT05578222** · PHASE2 · UNKNOWN · sponsor: **Tianjin Chest Hospital** · enrollment: 30 (estimated)

## Conditions studied

- NSCLC With COPD

## Interventions

- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT05578222
- **Lead sponsor:** Tianjin Chest Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-10-10
- **Primary completion:** 2023-12-12
- **Final completion:** 2024-12-12
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2022-10-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05578222

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05578222, "Pembrolizumab as First-line Treatment for Advanced NSCLC Complicated With COPD". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT05578222. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*